Literature DB >> 29548558

A prospective cohort study of hepatic toxicity after stereotactic body radiation therapy for hepatocellular carcinoma.

Ting-Shi Su1, Ren Luo2, Ping Liang3, Tao Cheng4, Ying Zhou5, Yong Huang5.   

Abstract

PURPOSE: To build and validate multivariate normal tissue complication probability (NTCP) models for radiation-induced hepatic toxicity (RIHT) after stereotactic body radiation therapy (SBRT).
METHODS: Eighty-five patients with hepatocellular carcinoma (HCC) in a phase II clinical trial were enroled. A progression of at least 1 or 2 points in the Child-Pugh (CP) score post-SBRT was classified as RIHT (≥1 or ≥2). NTCP models for RIHT (≥1 or ≥2) were developed using logistic regression. Nomograms for each model were formulated. The cut-off point of each independent dosimetric risk factor was obtained using receiver-operating characteristic (ROC) analysis. We used an independent cohort (101 patients) for model validation.
RESULTS: Twenty (23.5%) and 12 (14.2%) patients experienced RIHT (≥1) and RIHT (≥2), respectively. V15, VS10, and pretreatment CP (pre-CP) were the optimal predictors for RIHT (≥1 and ≥2) modelling. V15 ≤33.1% and VS10 ≥416.2 mL for RIHT (≥1), and V15 ≤21.5% and VS10 ≥621.8 mL for RIHT (≥2), were the cut-off points. Four NTCP models and their nomograms were generated. These models and nomograms showed good prediction performance (area under the curve (AUC), 0.83-0.89). Our NTCP model (RIHT ≥2) based on V15 plus pre-CP performed well (AUC = 0.78) in a validation cohort.
CONCLUSION: V15, VS10, and pre-CP are crucial predictors for RIHT (≥1 and ≥2). Our NTCP models and nomograms were conducive to obtain individual constraints for patients with HCC. REGISTRATION NUMBER: ChiCTR-IIC-16008233.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Child–Pugh; Hepatic toxicity; Hepatocellular carcinoma; Nomogram; Normal tissue complication probability; Stereotactic body radiation therapy

Mesh:

Year:  2018        PMID: 29548558     DOI: 10.1016/j.radonc.2018.02.031

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  10 in total

1.  Dosimetric Analysis and Normal-Tissue Complication Probability Modeling of Child-Pugh Score and Albumin-Bilirubin Grade Increase After Hepatic Irradiation.

Authors:  Jennifer Pursley; Issam El Naqa; Nina N Sanford; Bridget Noe; Jennifer Y Wo; Christine E Eyler; Matthew Hwang; Kristy K Brock; Beow Y Yeap; John A Wolfgang; Theodore S Hong; Clemens Grassberger
Journal:  Int J Radiat Oncol Biol Phys       Date:  2020-04-27       Impact factor: 7.038

2.  Efficacy and Safety of SBRT Combined With Camrelizumab and Apatinib in HCC Patients With PVTT: Study Protocol of a Randomized Controlled Trial.

Authors:  Yue Hu; Tingting Qin; Shuang Li; Tao Zhang; Jun Xue
Journal:  Front Oncol       Date:  2020-08-26       Impact factor: 6.244

3.  Impact of potentially variable RBE in liver proton therapy.

Authors:  Yizheng Chen; Clemens Grassberger; Junli Li; Theodore S Hong; Harald Paganetti
Journal:  Phys Med Biol       Date:  2018-09-21       Impact factor: 3.609

Review 4.  Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma: Current Trends and Controversies.

Authors:  Stephanie K Schaub; Pehr E Hartvigson; Michael I Lock; Morten Høyer; Thomas B Brunner; Higinia R Cardenes; Laura A Dawson; Edward Y Kim; Nina A Mayr; Simon S Lo; Smith Apisarnthanarax
Journal:  Technol Cancer Res Treat       Date:  2018-01-01

5.  Development and Evaluation of Nomograms to Predict the Cancer-Specific Mortality and Overall Mortality of Patients with Hepatocellular Carcinoma.

Authors:  Xiaofeng Ni; Ding Li; Shengjie Dai; Hao Pan; Hongwei Sun; Jianyang Ao; Lei Chen; Hongru Kong
Journal:  Biomed Res Int       Date:  2021-03-29       Impact factor: 3.411

6.  Optimal stereotactic body radiotherapy dosage for hepatocellular carcinoma: a multicenter study.

Authors:  Ting-Shi Su; Qiu-Hua Liu; Xiao-Fei Zhu; Ping Liang; Shi-Xiong Liang; Lin Lai; Ying Zhou; Yong Huang; Tao Cheng; Le-Qun Li
Journal:  Radiat Oncol       Date:  2021-04-21       Impact factor: 3.481

7.  A Prospective Study of Liver Regeneration After Radiotherapy Based on a New (Su'S) Target Area Delineation.

Authors:  Ting-Shi Su; Li-Qing Li; Shi-Xiong Liang; Bang-De Xiang; Jian-Xu Li; Jia-Zhou Ye; Le-Qun Li
Journal:  Front Oncol       Date:  2021-08-26       Impact factor: 6.244

8.  Stereotactic Body Radiation Therapy vs. Transarterial Chemoembolization in Inoperable Barcelona Clinic Liver Cancer Stage a Hepatocellular Carcinoma: A Retrospective, Propensity-Matched Analysis.

Authors:  Ting-Shi Su; Ping Liang; Ying Zhou; Yong Huang; Tao Cheng; Song Qu; Long Chen; Bang-De Xiang; Chang Zhao; De-Jia Huang; Shi-Xiong Liang; Le-Qun Li
Journal:  Front Oncol       Date:  2020-03-24       Impact factor: 6.244

Review 9.  Radiomics for liver tumours.

Authors:  Constantin Dreher; Philipp Linde; Judit Boda-Heggemann; Bettina Baessler
Journal:  Strahlenther Onkol       Date:  2020-04-15       Impact factor: 3.621

10.  Radiomics-Based Predictive Model of Radiation-Induced Liver Disease in Hepatocellular Carcinoma Patients Receiving Stereo-Tactic Body Radiotherapy.

Authors:  Po-Chien Shen; Wen-Yen Huang; Yang-Hong Dai; Cheng-Hsiang Lo; Jen-Fu Yang; Yu-Fu Su; Ying-Fu Wang; Chia-Feng Lu; Chun-Shu Lin
Journal:  Biomedicines       Date:  2022-03-03
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.